Cost Minimisation Model
Added on 28/04/2023
How to prove the ‘added value’ when the concerned innovation is beneficial without producing ‘health’ in a direct way?
How to prove the ‘added value’ when the concerned innovation is beneficial without producing ‘health’ in a direct way?
A model contains a large amount of inputs and every single input will be surrounded with uncertainty and the end result will be a translation of the composite effect of all inputs and their potential variance.
Do you understand the potential impact of using 2 independent datasets? In this blog, we provide you a taste of some basic insights.
Always wondered how health economic models work? Good news: this blog is developed to guide you through the basic elements of ‘health state transition models’.
To estimate a launch date, some questions will pop-up. Based on the answers, (in combination with a strong strategy) a realistic estimate of the procedural time will become valid.
We all know that the pathway between the ‘eureka’ moment and the implementation is long. If needed the regulatory bodies can decide to initiate a ‘fast track procedure’.
‘Success’ is usually the achievement of an expected outcome which is driven by a predefined process.
If you estimate a market share and present this to the sales and marketing department, their input will show high variance. How can you reduce that variance and how can you achieve the best and realistic estimation of the market shares?
HTA bodies should take indirect costs in the scope to assess the cost/benefit of innovation.
A robust budget impact estimation starts with knowledge about the volume of patients. But, how to best estimate the optimal target population?